SSX1抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: K562 cells, Primary antibody: P08810(SSX1 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

The SSX1 antibody is a valuable tool in cancer research, particularly in studying malignancies associated with the SSX gene family. SSX1. a member of the SSX (synovial sarcoma X breakpoint) gene family, encodes a cancer-testis antigen (CTA) normally expressed in germ cells but aberrantly reactivated in various cancers. SSX proteins are implicated in transcriptional regulation and chromatin remodeling. SSX1 gained prominence due to its role in synovial sarcoma, where chromosomal translocation t(X;18) fuses SSX1 (or SSX2/SSX4) with the SS18 gene, producing an oncogenic SS18-SSX fusion protein that drives tumorigenesis by disrupting epigenetic regulators.

SSX1 antibodies are primarily used to detect SSX1 protein expression in research and diagnostic settings. They help identify SSX1-positive tumors, characterize subcellular localization (nuclear/cytoplasmic), and study its interaction with proteins like Polycomb repressive complexes. Commercially available SSX1 antibodies include monoclonal and polyclonal variants validated for techniques like immunohistochemistry, Western blotting, and immunofluorescence. Challenges include cross-reactivity with other SSX family members (SSX2-SSX9) due to high sequence homology, necessitating careful validation. Clinically, SSX1 is explored as a biomarker and immunotherapy target, with efforts to develop SSX1-directed CAR-T cells or vaccines. However, its restricted normal tissue expression and tumor-specific reactivation make it a promising but still emerging target in precision oncology.